Axovant Sciences Ltd. (NASDAQ:AXON) has made a -13.28% comeback from a 12-month low price of $1.77. It was seen -19.63% lower, changing the price to $1.53, when the closing bell rang on 02/12/2018. At recent session, the prices were hovering between $1.47 and $1.58. This company shares are 651.63% off its target price of $11.5 and the current market capitalization stands at $167.96M. The recent change has given its price a -59.21% deficit over SMA 50 and -94.51% deficit over its 52-week high. The stock witnessed -32.38% declines, -69.84% declines and -93.11% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AXON’s volatility during a week at 8.37% and during a month it has been found around 6.81%.Axovant Sciences Ltd. (AXON) Top Holders
Institutional investors currently hold around $208 million or 28.8% in AXON stock. Look at its top three institutional owners. Qvt Financial Lp owns $143.25 million in Axovant Sciences Ltd., which represents roughly 85.29% of the company’s market cap and approximately 68.87% of the institutional ownership. Similar statistics are true for the second largest owner, Janus Capital Management Llc, which owns 4,498,991 shares of the stock are valued at $8.59 million. The third largest holder is Primecap Management Co/Ca/, which currently holds $6.52 million worth of this stock and that ownership represents nearly 3.88% of its market capitalization.
At the end of 09/30/2017 reporting period, 75 institutional holders increased their position in Axovant Sciences Ltd. (NASDAQ:AXON) by some 12,640,915 shares, 59 decreased positions by 16,490,713 and 15 held positions by 79,801,493. That puts total institutional holdings at 108,933,121 shares, according to SEC filings. The stock grabbed 35 new institutional investments totaling 3,497,075 shares while 34 institutional investors sold out their entire positions totaling 8,320,772 shares.Axovant Sciences Ltd. (NASDAQ:AXON) Insider Trades
Multiple company employees have indulged in significant insider trading. Axovant Sciences Ltd. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Principal Executive Officer Hung David has acquired 539,375 shares of Axovant Sciences Ltd. (AXON) in trading session dated Apr. 17, 2017. These shares are worth $10,000,013 and were traded at $18.54 each. The SEC filing shows that Falberg Kathryn E performed a purchase of 53,937 shares. The Director added these shares by way of transaction on Apr. 17, 2017. The company’s shares were assimilated at $18.54 per share worth to an investment of some $999,992 on account of Falberg Kathryn E.
Director, Vernon W Anthony, purchased 53,937 common shares of Axovant Sciences Ltd. (AXON) in the open market. In a transaction dated Apr. 17, 2017, the shares were bought at an average price of $18.54, giving away a sum of $999,992. After this purchase, 53,937 common shares of AXON are directly owned by the insider, with total stake valued at $82,524.
In the transaction dated Mar. 10, 2016, the great number of shares acquired came courtesy the Pres&Chief Commercial Officer; Altmeyer Mark added a total of 2,300 shares at an average price of $11.14, amounting to approximately $25,622. The insider now directly owns 2,300 shares worth $3,519.Axovant Sciences Ltd. (AXON) Analyst Guide
Several analysts have released their opinion on Axovant Sciences Ltd. (NASDAQ:AXON), with 2 analysts believing it is a strong buy. Whereas 6 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation.